CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.150
+0.180 (4.53%)
At close: Nov 25, 2025, 4:00 PM EST
4.240
+0.090 (2.17%)
Pre-market: Nov 26, 2025, 5:15 AM EST
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $5.96M in the quarter ending September 30, 2025, a decrease of -82.16%. This brings the company's revenue in the last twelve months to $113.63M, down -10.26% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.
Revenue (ttm)
$113.63M
Revenue Growth
-10.26%
P/S Ratio
4.27
Revenue / Employee
$939,099
Employees
121
Market Cap
703.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CTMX News
- 21 hours ago - CytomX Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire
- 7 days ago - CytomX Therapeutics: Leaning Into The Hype, But What's Next? - Seeking Alpha
- 12 days ago - CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 15 days ago - Targeting Adhesion Molecules With ADC's: The Bet Of CytomX - Seeking Alpha
- 18 days ago - CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 21 days ago - Top Biotech Stocks Riding The Rally - Seeking Alpha
- 21 days ago - CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire